Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Leases (2016 - 2017)

Neurocrine Biosciences filings provide 8 years of Current Leases readings, the most recent being $62000.0 for Q4 2017.

  • On a quarterly basis, Current Leases fell 73.73% to $62000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $62000.0, a 73.73% decrease, with the full-year FY2017 number at $62000.0, down 73.73% from a year prior.
  • Current Leases hit $62000.0 in Q4 2017 for Neurocrine Biosciences, down from $121000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $556000.0 in Q2 2015 to a low of $62000.0 in Q4 2017.
  • Median Current Leases over the past 5 years was $412500.0 (2013), compared with a mean of $352900.0.
  • Biggest five-year swings in Current Leases: soared 84.39% in 2013 and later plummeted 73.73% in 2017.
  • Neurocrine Biosciences' Current Leases stood at $416000.0 in 2013, then increased by 12.26% to $467000.0 in 2014, then decreased by 8.35% to $428000.0 in 2015, then plummeted by 44.86% to $236000.0 in 2016, then plummeted by 73.73% to $62000.0 in 2017.
  • The last three reported values for Current Leases were $62000.0 (Q4 2017), $121000.0 (Q3 2017), and $181000.0 (Q2 2017) per Business Quant data.